Emmons MF - Search Results

1

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. Turner JG, et al. Among authors: emmons mf. J Cancer. 2013 Sep 10;4(8):614-25. doi: 10.7150/jca.7080. eCollection 2013. J Cancer. 2013. PMID: 24155773 Free PMC article.

2

Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.

Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS. Hazlehurst LA, et al. Cancer Res. 2006 Feb 15;66(4):2338-45. doi: 10.1158/0008-5472.CAN-05-3256. Cancer Res. 2006. PMID: 16489039

3

Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.

Emmons M, Boulware D, Sullivan DM, Hazlehurst LA. Emmons M, et al. Biochem Pharmacol. 2006 Jun 28;72(1):11-8. doi: 10.1016/j.bcp.2006.03.017. Epub 2006 Mar 28. Biochem Pharmacol. 2006. PMID: 16678798

4

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.

Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Bewry NN, et al. Among authors: emmons mf. Mol Cancer Ther. 2008 Oct;7(10):3169-75. doi: 10.1158/1535-7163.MCT-08-0314. Mol Cancer Ther. 2008. PMID: 18852120 Free PMC article.

5

HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.

Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA. Nair RR, et al. Among authors: emmons mf. Mol Cancer Ther. 2009 Aug;8(8):2441-51. doi: 10.1158/1535-7163.MCT-09-0113. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671765 Free PMC article.

6

Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Turner JG, et al. Among authors: emmons mf. Cancer Res. 2009 Sep 1;69(17):6899-905. doi: 10.1158/0008-5472.CAN-09-0484. Epub 2009 Aug 18. Cancer Res. 2009. PMID: 19690141 Free PMC article.

7

Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Emmons MF, et al. Mol Cancer Ther. 2011 Dec;10(12):2257-66. doi: 10.1158/1535-7163.MCT-11-0149. Epub 2011 Oct 6. Mol Cancer Ther. 2011. PMID: 21980133 Free PMC article.

8

Emerging strategies for targeting cell adhesion in multiple myeloma.

Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA. Nair RR, et al. Among authors: emmons mf. Adv Pharmacol. 2012;65:143-89. doi: 10.1016/B978-0-12-397927-8.00006-3. Adv Pharmacol. 2012. PMID: 22959026 Review.

9

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. Gebhard AW, et al. Among authors: emmons mf. Mol Cancer Ther. 2013 Nov;12(11):2446-58. doi: 10.1158/1535-7163.MCT-13-0310. Epub 2013 Sep 18. Mol Cancer Ther. 2013. PMID: 24048737 Free PMC article.

10

MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.

Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, Silva A, Hazlehurst LA. Emmons MF, et al. Sci Rep. 2017 Jun 2;7(1):2685. doi: 10.1038/s41598-017-02713-0. Sci Rep. 2017. PMID: 28578393 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters